Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG) Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2019
NCT03839771
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Refractory, with Excess of Blasts (Phase 3)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Preleukemia (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4